{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:25:49Z","timestamp":1784780749775,"version":"3.55.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The advent of COVID-19 has highlighted the value of repurposing existing antiviral medications and the importance of developing efficient analytical methods to assist their quality control. Simultaneous determination of multiple agents saves time and resources in pharmaceutical analysis. Moreover, the analytical demand during health emergencies underscores the need for validated, rapid, and reliable methods that can support both therapeutic evaluation and regulatory decisions. In this study, we developed and optimized a reversed-phase high-performance liquid chromatography (RP-HPLC) method to measure four repurposed antiviral drugs: favipiravir, sofosbuvir, ledipasvir, and remdesivir. A Box\u2013Behnken design (BBD) approach was employed to study how buffer pH, the amount of organic solvent in the mobile phase, and flow rate affect key outcomes like resolution and run time. The separation was done on INERTSIL ODS-3 C18 column (5\u00a0\u03bcm, 250\u2009\u00d7\u20094.6\u00a0mm) under isocratic elution conditions using acetonitrile (50:50, v\/v) and ammonium formate buffer (0.02\u00a0M, adjusted to pH 2.8 with formic acid) as the mobile phase at flow rate 1 mL\/min. Detection was performed at 240\u00a0nm. The method demonstrated good system suitability and met ICH Q2 (R2) validation standards, exhibiting satisfactory linearity (R\u00b2 &gt; 0.999), accuracy (recoveries within 98\u2013102%), and precision (RSD\u2009&lt;\u20092%). The sustainability of the proposed method was comprehensively evaluated using AGREE, MoGAPI, BAGI, and RAPI tools to assess its greenness, blueness, and whiteness. The proposed method offers a practical and efficient analytical platform for quality control laboratories, enabling reliable routine analysis of multiple antiviral agents in pharmaceutical products, particularly for post-pandemic preparedness and therapeutic surveillance.<\/jats:p>","DOI":"10.1038\/s41598-026-50549-4","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T19:13:54Z","timestamp":1778526834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Box\u2013Behnken design\u2013assisted RP-HPLC method development and optimization for simultaneous determination of four antiviral drugs in pharmaceutical dosage forms"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2521-4358","authenticated-orcid":false,"given":"Fatma H.","family":"Ghazy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzia I.","family":"El-Bagary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar H.","family":"Fahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally T.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"50549_CR1","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/ana.410030524","volume":"3","author":"J Moossy","year":"1978","unstructured":"Moossy, J. Infectious diseases and PML. Ann. Neurol. 3, 468\u2013468 (1978).","journal-title":"Ann. Neurol."},{"key":"50549_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/20587384211002621","author":"S Kausar","year":"2021","unstructured":"Kausar, S. et al. A review: Mechanism of action of antiviral drugs. Int. J. Immunopathol. Pharmacol. https:\/\/doi.org\/10.1177\/20587384211002621 (2021).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"50549_CR3","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1080\/10408347.2021.1908111","volume":"52","author":"O Selcuk","year":"2022","unstructured":"Selcuk, O., Demir, Y., Erkmen, C., Y\u0131ld\u0131r\u0131m, S. & Uslu, B. Analytical methods for determination of antiviral drugs in different matrices: Recent advances and trends. Crit. Rev. Anal. Chem. 52, 1662\u20131693 (2022).","journal-title":"Crit. Rev. Anal. Chem."},{"key":"50549_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules26082123","volume":"26","author":"L Fical","year":"2021","unstructured":"Fical, L. et al. Determination of antiviral drugs and their metabolites using micro-solid phase extraction and UHPLC-MS\/MS in reversed-phase and hydrophilic interaction chromatography modes. Molecules 26, 1\u201322 (2021).","journal-title":"Molecules"},{"key":"50549_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.113935","author":"K Habler","year":"2021","unstructured":"Habler, K. et al. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC\u2013MS\/MS method in human serum. J. Pharm. Biomed. Anal. https:\/\/doi.org\/10.1016\/j.jpba.2021.113935 (2021).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"50549_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ddstr.2011.10.002","volume":"8","author":"TI Oprea","year":"2011","unstructured":"Oprea, T. I. et al. Drug repurposing from an academic perspective. Drug Discov Today Ther. Strateg. 8, 61\u201369 (2011).","journal-title":"Drug Discov Today Ther. Strateg"},{"key":"50549_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2018","unstructured":"Pushpakom, S. et al. Drug repurposing: Progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2018).","journal-title":"Nat. Rev. Drug Discov"},{"key":"50549_CR8","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","volume":"26","author":"B Mercorelli","year":"2018","unstructured":"Mercorelli, B., Pal\u00f9, G. & Loregian, A. Drug repurposing for viral infectious diseases: How far are we?. Trends Microbiol. 26, 865\u2013876 (2018).","journal-title":"Trends Microbiol."},{"key":"50549_CR9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02680-20","author":"KA Gammeltoft","year":"2021","unstructured":"Gammeltoft, K. A. et al. Hepatitis c virus protease inhibitors show differential efficacy and interactions with remdesivir for treatment of SARS-CoV-2 in vitro. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02680-20 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"50549_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ajg.2022.04.005","volume":"23","author":"MA Medhat","year":"2022","unstructured":"Medhat, M. A. et al. Sofosbuvir\/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals. Arab J. Gastroenterol. 23, 165\u2013171 (2022).","journal-title":"Arab J. Gastroenterol."},{"key":"50549_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","volume":"383","author":"E Lawitz","year":"2014","unstructured":"Lawitz, E. et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 383, 515\u2013523 (2014).","journal-title":"Lancet"},{"key":"50549_CR12","unstructured":"Sancovir 200\u00a0mg | Sana Pharma. https:\/\/www.sana-pharma.com\/?q=node\/6131"},{"key":"50549_CR13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.25122\/jml-2021-0175","volume":"15","author":"MAS Elgohary","year":"2022","unstructured":"Elgohary, M. A. S. et al. Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial. J. Med. Life. 15, 350\u2013358 (2022).","journal-title":"J. Med. Life"},{"key":"50549_CR14","doi-asserted-by":"publisher","first-page":"654","DOI":"10.36348\/sjmps.2020.v06i10.003","volume":"6","author":"SA Raslan","year":"2020","unstructured":"Raslan, S. A., Shehata, E. M., Raslan, M. & Sabri, N. A. Management of second wave of COVID 19 with ledipasvir\/sofosbuvir combination. Will it work? A review article. Saudi J. Med. Pharm. Sci. 6, 654\u2013657 (2020).","journal-title":"Saudi J. Med. Pharm. Sci."},{"key":"50549_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s43094-023-00519-8","author":"S Gamal","year":"2023","unstructured":"Gamal, S., Mandour, A. A., Mohamed, G. G., Salih, S. A. & Ahmed, D. A. Simultaneous spectrophotometric determination of recombined sofosbuvir, ledipasvir and paracetamol together as commonly repurposed drugs for COVID-19 treatment. Futur. J. Pharm. Sci. https:\/\/doi.org\/10.1186\/s43094-023-00519-8 (2023).","journal-title":"Futur. J. Pharm. Sci."},{"key":"50549_CR16","first-page":"239","volume":"91","author":"A Nourian","year":"2020","unstructured":"Nourian, A. & Khalili, H. Sofosbuvir as a potential option for the treatment of COVID-19. Acta Biomed. 91, 239\u2013241 (2020).","journal-title":"Acta Biomed."},{"key":"50549_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112527","volume":"201","author":"C Liang","year":"2020","unstructured":"Liang, C. et al. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. Eur. J. Med. Chem. 201, 112527 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"50549_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101615","volume":"34","author":"JA Al-Tawfiq","year":"2020","unstructured":"Al-Tawfiq, J. A., Al-Homoud, A. H. & Memish, Z. A. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med. Infect. Dis. 34, 101615 (2020).","journal-title":"Travel Med. Infect. Dis."},{"key":"50549_CR19","first-page":"10","volume":"34","author":"JJ Malin","year":"2021","unstructured":"Malin, J. J., Su\u00e1rez, I., Priesner, V. & F\u00e4tkenheuer, G. Remdesivir against COVID-19 and other viral diseases. Clin. Microbiol. Rev. 34, 10\u2013128 (2021).","journal-title":"Clin. Microbiol. Rev."},{"key":"50549_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25102343","author":"K Parang","year":"2020","unstructured":"Parang, K., El-Sayed, N. S., Kazeminy, A. J. & Tiwari, R. K. Comparative antiviral activity of remdesivir and anti-HIV nucleoside analogs against human coronavirus 229E (HCOV-229E). Molecules https:\/\/doi.org\/10.3390\/molecules25102343 (2020).","journal-title":"Molecules"},{"key":"50549_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/13596535221082773","volume":"27","author":"T Cihlar","year":"2022","unstructured":"Cihlar, T. & Mackman, R. L. Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. Antivir. Ther. 27, 1\u201312 (2022).","journal-title":"Antivir. Ther."},{"key":"50549_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10020273","volume":"10","author":"R \u0141agocka","year":"2021","unstructured":"\u0141agocka, R., Dziedziejko, V., K\u0142os, P. & Pawlik, A. Favipiravir in therapy of viral infections. J. Clin. Med. 10, 1\u201316 (2021).","journal-title":"J. Clin. Med."},{"key":"50549_CR23","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1093\/jac\/dkaa171","volume":"75","author":"EA Coomes","year":"2020","unstructured":"Coomes, E. A. & Haghbayan, H. Favipiravir, an antiviral for COVID-19? J. Antimicrob. Chemother. 75, 2013\u20132014 (2020).","journal-title":"J. Antimicrob. Chemother."},{"key":"50549_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.32607\/actanaturae.11652","volume":"14","author":"ID Konstantinova","year":"2022","unstructured":"Konstantinova, I. D., Andronova, V. L., Fateev, I. V. & Esipov, R. S. Favipiravir and its structural analogs: Antiviral activity and synthesis methods. Acta Naturae 14, 16\u201338 (2022).","journal-title":"Acta Naturae"},{"key":"50549_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-020-01412-z","volume":"17","author":"DB Shrestha","year":"2020","unstructured":"Shrestha, D. B. et al. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: A rapid systematic review and meta-analysis. Virol. J. 17, 141 (2020).","journal-title":"Virol. J."},{"key":"50549_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-021-06164-x","volume":"21","author":"T Manabe","year":"2021","unstructured":"Manabe, T., Kambayashi, D., Akatsu, H. & Kudo, K. Favipiravir for the treatment of patients with COVID-19: A systematic review and meta-analysis. BMC Infect. Dis. 21, 1\u201313 (2021).","journal-title":"BMC Infect. Dis."},{"key":"50549_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00216-010-3748-y","volume":"398","author":"R Martino","year":"2010","unstructured":"Martino, R., Malet-Martino, M., Gilard, V. & Balayssac, S. Counterfeit drugs: Analytical techniques for their identification. Anal. Bioanal. Chem. 398, 77\u201392 (2010).","journal-title":"Anal. Bioanal. Chem."},{"key":"50549_CR28","doi-asserted-by":"publisher","DOI":"10.2147\/rrtm.s39354","author":"B Glass","year":"2014","unstructured":"Glass, B. Counterfeit drugs and medical devices in developing countries. Res. Rep. Trop. Med. https:\/\/doi.org\/10.2147\/rrtm.s39354 (2014).","journal-title":"Res. Rep. Trop. Med."},{"key":"50549_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2014-006290","volume":"5","author":"F El-Jardali","year":"2015","unstructured":"El-Jardali, F. et al. Interventions to combat or prevent drug counterfeiting: A systematic review. BMJ Open 5, 1\u201311 (2015).","journal-title":"BMJ Open"},{"key":"50549_CR30","first-page":"71","volume":"46","author":"H Bhutani","year":"2014","unstructured":"Bhutani, H., Kurmi, M., Singh, S., Beg, S. & Singh, B. Quality by design (QbD) in analytical sciences: An overview. Pharma Times. 46, 71\u201375 (2014).","journal-title":"Pharma Times"},{"key":"50549_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43094-024-00706-1","volume":"10","author":"A Bairagi","year":"2024","unstructured":"Bairagi, A., Kothrukar, R., Chikhale, H., Kosanam, S. & Borse, L. AQbD-novel strategy for analytical methods. Futur. J. Pharm. Sci. 10, 1\u20139 (2024).","journal-title":"Futur. J. Pharm. Sci."},{"key":"50549_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/plants11212960","author":"G Park","year":"2022","unstructured":"Park, G., Kim, M. K., Go, S. H., Choi, M. & Jang, Y. P. Analytical Quality by Design (AQbD) approach to the development of analytical procedures for medicinal plants. Plants https:\/\/doi.org\/10.3390\/plants11212960 (2022).","journal-title":"Plants"},{"issue":"1","key":"50549_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91341-w","volume":"11","author":"MK Kim","year":"2021","unstructured":"Kim, M. K., Park, S. C., Park, G., Choi, E. & Ji, Y. Analytical quality by design methodology for botanical raw material analysis: A case study of flavonoids in Genkwa Flos. Sci. Rep. 1\u201314. https:\/\/doi.org\/10.1038\/s41598-021-91341-w (2021).","journal-title":"Sci. Rep."},{"key":"50549_CR34","first-page":"1784","volume":"23","author":"T Tome","year":"2019","unstructured":"Tome, T., Nina, Z., Zdenko, C. & Obreza, A. Development and optimization of liquid chromatography analytical methods by using AQbD principles: Overview and recent advances. Am. Omega 23, 1784\u20131802 (2019).","journal-title":"Am. Omega"},{"key":"50549_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/17425247.2018.1504768","volume":"15","author":"V Mishra","year":"2018","unstructured":"Mishra, V., Thakur, S., Patil, A. & Shukla, A. Quality by design (QbD) approaches in current pharmaceutical set-up. Expert Opin. Drug Deliv. 15, 737\u2013758 (2018).","journal-title":"Expert Opin. Drug Deliv."},{"key":"50549_CR36","doi-asserted-by":"publisher","DOI":"10.53388\/PR202202010","volume":"2","author":"N Minocha","year":"2022","unstructured":"Minocha, N., Saini, S. & Pandey, P. Design of experiments: How to develop and optimize drug delivery systems. TMR Pharmacol. Res. 2, 10 (2022).","journal-title":"TMR Pharmacol. Res."},{"key":"50549_CR37","doi-asserted-by":"publisher","first-page":"452","DOI":"10.4274\/tjps.galenos.2020.08522","volume":"18","author":"D Ghose","year":"2021","unstructured":"Ghose, D. et al. QbD-based formulation optimization and characterization of polymeric nanoparticles of cinacalcet hydrochloride with improved biopharmaceutical attributes. Turk. J. Pharm. Sci. 18, 452\u2013464 (2021).","journal-title":"Turk. J. Pharm. Sci."},{"key":"50549_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124163","volume":"657","author":"C Camacho Vieira","year":"2024","unstructured":"Camacho Vieira, C., Peltonen, L., Karttunen, A. P. & Ribeiro, A. J. Is it advantageous to use quality by design (QbD) to develop nanoparticle-based dosage forms for parenteral drug administration?. Int. J. Pharm. 657, 124163 (2024).","journal-title":"Int. J. Pharm."},{"key":"50549_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4274\/tjps.galenos.2022.05335","volume":"20","author":"H Vancha","year":"2023","unstructured":"Vancha, H. et al. Analytical quality by design driven development and validation of UV-Visible spectrophotometric method for quantification of xanthohumol in bulk and solid lipid nanoparticles. Turk. J. Pharm. Sci. 20, 165\u2013175 (2023).","journal-title":"Turk. J. Pharm. Sci."},{"key":"50549_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2025.107276","author":"M Salamah","year":"2025","unstructured":"Salamah, M. & Sipos, B. Development and validation of a novel isocratic RP-HPLC method using AQbD approach for the quantification of favipiravir. Eur. J. Pharm. Sci. https:\/\/doi.org\/10.1016\/j.ejps.2025.107276 (2025).","journal-title":"Eur. J. Pharm. Sci."},{"key":"50549_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bmad093","author":"MB Sangani","year":"2024","unstructured":"Sangani, M. B. An eco-friendly RP-HPLC method development and validation for quantification of favipiravir in bulk and tablet dosage form followed by forced degradation study. J. Chromatogr. Sci. https:\/\/doi.org\/10.1093\/chromsci\/bmad093 (2024).","journal-title":"J. Chromatogr. Sci."},{"key":"50549_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13065-025-01610-2","volume":"19","author":"AE Ibrahim","year":"2025","unstructured":"Ibrahim, A. E. et al. A quality \u2011 by \u2011 design optimized LC method for navigating degradation kinetics and quantification of favipiravir in the presence of degradation products and manufacturing impurities. BMC Chem. 19, 1\u201315 (2025).","journal-title":"BMC Chem."},{"key":"50549_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/cem.3548","volume":"38","author":"AF Abdel Hakiem","year":"2024","unstructured":"Abdel Hakiem, A. F., Boushra, J. M., Noureldeen, D. A. M., Lashien, A. S. & Attia, T. Z. Response surface experimental design for simultaneous chromatographic determination of two antiviral agents \u201cfavipiravir and remdesivir\u201d in pharmaceuticals and spiked plasma samples. J. Chemom. 38, e3548 (2024).","journal-title":"J. Chemom."},{"key":"50549_CR44","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s10337-016-3179-9","volume":"79","author":"B Zaman","year":"2016","unstructured":"Zaman, B., Siddique, F. & Hassan, W. RP \u2011 HPLC method for simultaneous determination of sofosbuvir and ledipasvir in tablet dosage form and its application to in vitro dissolution studies. Chromatographia 79, 1605\u20131613 (2016).","journal-title":"Chromatographia"},{"key":"50549_CR45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.pharma.2017.07.005","volume":"76","author":"MM Baker","year":"2018","unstructured":"Baker, M. M., El-Kafrawy, D. S., Mahrous, M. S. & Belal, T. S. Validated spectrophotometric and chromatographic methods for analysis of the recently approved hepatitis C antiviral combination ledipasvir and sofosbuvir. Ann. Pharm. Fr. 76, 16\u201331 (2018).","journal-title":"Ann. Pharm. Fr."},{"key":"50549_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10337-025-04386-8","volume":"88","author":"ME \u00d6zdemirhan","year":"2025","unstructured":"\u00d6zdemirhan, M. E., \u00d6zen, G., Nemutlu, E. & Ganciclovir, G. A. N. An RP \u2011 HPLC method for the simultaneous analysis of selected antiviral drugs. Chromatographia 88, 179\u2013191 (2025).","journal-title":"Chromatographia"},{"key":"50549_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2020.105251","volume":"158","author":"HI EL-Shorbagy","year":"2020","unstructured":"EL-Shorbagy, H. I., Elsebaei, F., Hammad, S. F. & El-Brashy, A. M. A green stability-indicating RP-HPLC-UV method using factorial design for determination of ribavirin, sofosbuvir and ledipasvir: Application to average content, acid degradation kinetics and in vitro drug interactions study. Microchem. J. 158, 105251 (2020).","journal-title":"Microchem. J."},{"key":"50549_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2022.108344","volume":"186","author":"HM Mohamed","year":"2023","unstructured":"Mohamed, H. M., Saad, A. S., Morsi, A. M. & Essam, H. M. Green RP-HPLC method for simultaneous determination of sofosbuvir, ledipasvir, velpatasvir antivirals and beyond in their bulk material and co-formulated products. Microchem. J. 186, 108344 (2023).","journal-title":"Microchem. J."},{"key":"50549_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-09904-0","author":"MW Nassar","year":"2025","unstructured":"Nassar, M. W., Serag, A., Hasan, M. A. & Kamel, M. Development and validation of a RP-HPLC method for simultaneous determination of five COVID-19 antiviral drugs in pharmaceutical formulations. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-025-09904-0 (2025).","journal-title":"Sci. Rep."},{"key":"50549_CR50","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/03639045.2019.1593444","volume":"45","author":"MM Baker","year":"2019","unstructured":"Baker, M. M., Hammad, S. F. & Belal, T. S. Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Application to assay of dosage forms and dissolution studies. Drug Dev. Ind. Pharm. 45, 1111\u20131119 (2019).","journal-title":"Drug Dev. Ind. Pharm."},{"key":"50549_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.scp.2023.101202","volume":"35","author":"M Mabrouk","year":"2023","unstructured":"Mabrouk, M., Abdelfattah, I. I. & Mansour, F. R. Green method for determination of four anti-viral drugs using micellar liquid chromatography: Application to dosage form analysis. Sustain. Chem. Pharm. 35, 101202 (2023).","journal-title":"Sustain. Chem. Pharm."},{"key":"50549_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/separations10060346","author":"A Najmi","year":"2023","unstructured":"Najmi, A. et al. Optimization of chromatographic conditions with QbD for method development and validation of Bosutinib by HPLC: Applications in dosage forms and rat plasma analysis. Separations https:\/\/doi.org\/10.3390\/separations10060346 (2023).","journal-title":"Separations"},{"key":"50549_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/separations9110361","volume":"9","author":"SNH Azmi","year":"2022","unstructured":"Azmi, S. N. H. et al. Box\u2013Behnken Design based development of UV-reversed phase high performance liquid chromatographic method for determination of ascorbic acid in tablet formulations. Separations 9, 1\u201321 (2022).","journal-title":"Separations"},{"key":"50549_CR54","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1080\/10826076.2015.1087409","volume":"38","author":"NK Garg","year":"2015","unstructured":"Garg, N. K., Sharma, G., Singh, B., Nirbhavane, P. & Katare, O. P. Quality by design (QbD)-based development and optimization of a simple, robust RP-HPLC method for the estimation of methotrexate. J. Liq. Chromatogr. Relat. Technol. 38, 1629\u20131637 (2015).","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"50549_CR55","first-page":"1","volume":"9","author":"W Imanulkhan, Setyaningsih","year":"2020","unstructured":"Imanulkhan, Setyaningsih, W., Rohman, A. & Palma, M. Development and validation of hplc-dad method for simultaneous determination of seven food additives and caffeine in powdered drinks. Foods 9, 1\u201312 (2020).","journal-title":"Foods"},{"key":"50549_CR56","first-page":"058","volume":"7","author":"NK Prabaningdyah","year":"2017","unstructured":"Prabaningdyah, N. K., Riyanto, S., Rohman, A. & Siregar, C. Application of HPLC and response surface methodology for simultaneous determination of curcumin and desmethoxy curcumin in Curcuma syrup formulation. J. Appl. Pharm. Sci. 7, 058\u2013064 (2017).","journal-title":"J. Appl. Pharm. Sci."},{"key":"50549_CR57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/pca.2399","volume":"24","author":"JP Carini","year":"2013","unstructured":"Carini, J. P., Kaiser, S., Ortega, G. G. & Bassani, V. L. Development, optimisation and validation of a stability-indicating HPLC method of achyrobichalcone quantification using experimental designs. Phytochem. Anal. 24, 193\u2013200 (2013).","journal-title":"Phytochem. Anal."},{"key":"50549_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13065-022-00908-9","volume":"16","author":"EF Elkady","year":"2022","unstructured":"Elkady, E. F., Fouad, M. A. & Mozayad, A. N. Application of Box-Behnken experimental design and response surface methodology for selecting the optimum RP-HPLC conditions for the simultaneous determination of Methocarbamol, Indomethacin and Betamethasone in their pharmaceutical dosage form. BMC Chem. 16, 1\u201315 (2022).","journal-title":"BMC Chem."},{"key":"50549_CR59","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10337-017-3425-9","volume":"81","author":"BA Moussa","year":"2018","unstructured":"Moussa, B. A., Hashem, H. M. A., Mahrouse, M. A. & Mahmoud, S. T. Experimental design approach in HPLC method development: Application for the simultaneous determination of Sacubitril and Valsartan in presence of their impurities and investigation of degradation kinetics. Chromatographia 81, 139\u2013156 (2018).","journal-title":"Chromatographia"},{"key":"50549_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-40010-1","volume":"13","author":"YA Alanazi","year":"2023","unstructured":"Alanazi, Y. A. Condition optimization of eco-friendly RP-HPLC and MCR methods via Box\u2013Behnken design and Six Sigma approach for detecting antibiotic residues. Sci. Rep. 13, 1\u201328 (2023).","journal-title":"Sci. Rep."},{"key":"50549_CR61","unstructured":"Data Analysis Statistical & Process Improvement Tools | Minitab. https:\/\/www.minitab.com\/en-us\/"},{"key":"50549_CR62","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5530\/097484900279","volume":"15","author":"S Nashvia Adin","year":"2022","unstructured":"Nashvia Adin, S., Gupta, I., Aqil, M., Mujeeb, M. & Ahad, A. BBD driven optimization of extraction of therapeutically active Xanthanoid Mangiferin from Mangifera indica L. leaves and its antioxidant activity. Pharmacognosy Res. 15, 84\u201393 (2022).","journal-title":"Pharmacognosy Res."},{"key":"50549_CR63","doi-asserted-by":"publisher","first-page":"130","DOI":"10.22159\/ijap.2019v11i2.31285","volume":"11","author":"NBR Purba","year":"2019","unstructured":"Purba, N. B. R., Rohman, A. & Martono, S. The optimization of HPLC for quantitative analysis of Acid Orange 7 and Sudan II in cosmetic products using Box Behnken design. Int. J. Appl. Pharm. 11, 130\u2013137 (2019).","journal-title":"Int. J. Appl. Pharm."},{"key":"50549_CR64","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.5740\/jaoacint.18-0385","volume":"102","author":"\u015e Din\u00e7-Zor","year":"2019","unstructured":"Din\u00e7-Zor, \u015e., A\u015f\u00e7i, B., D\u00f6nmez, \u00d6. A. & Hacimustafa, \u00d6. Experimental design approach to optimize hplc separation of active ingredients, preservatives, and colorants in syrup formulation. J. AOAC Int. 102, 1523\u20131529 (2019).","journal-title":"J. AOAC Int."},{"key":"50549_CR65","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.bfopcu.2017.08.003","volume":"55","author":"KG Patel","year":"2017","unstructured":"Patel, K. G., Patel, A. T., Shah, P. A. & Gandhi, T. R. Multivariate optimization for simultaneous determination of aspirin and simvastatin by reverse phase liquid chromatographic method using AQbD approach. Bull. Fac. Pharmacy, Cairo Univ. 55, 293\u2013301 (2017).","journal-title":"Bull. Fac. Pharmacy, Cairo Univ."},{"key":"50549_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13065-023-01079-x","volume":"17","author":"EA Mostafa","year":"2023","unstructured":"Mostafa, E. A., El-Ashrey, M. K. & Mahmoud, S. T. An innovative combination of Box-Behnken design and ecofriendly approaches for the simultaneous determination of aspirin, clopidogrel, atorvastatin and rosuvastatin in their fixed-dose combination tablets. BMC Chem. 17, 1\u201320 (2023).","journal-title":"BMC Chem."},{"key":"50549_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s13721-013-0032-z","volume":"2","author":"W Sibanda","year":"2013","unstructured":"Sibanda, W. & Pretorius, P. Comparative study of the application of central composite face-centred (CCF) and Box\u2013Behnken designs (BBD) to study the effect of demographic characteristics on HIV risk in South Africa. Netw. Model. Anal. Heal Inf. Bioinforma. 2, 137\u2013146 (2013).","journal-title":"Netw. Model. Anal. Heal Inf. Bioinforma"},{"key":"50549_CR68","doi-asserted-by":"publisher","first-page":"23270","DOI":"10.1038\/s41598-024-74876-6","volume":"14","author":"R Perveen","year":"2024","unstructured":"Perveen, R. et al. Optimization study and application of box-behnken model for probing eggshell supported transition metals based catalysts to synthesize hydrazone & dihydropyrimidinones. Sci. Rep. 14, 23270 (2024).","journal-title":"Sci. Rep."},{"key":"50549_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-58381-4","volume":"14","author":"AN Mozayad","year":"2024","unstructured":"Mozayad, A. N., Fouad, M. A. & Elkady, E. F. Utilizing experimental design and desirability function in optimizing RP-HPLC method for simultaneous determination of some skeletal muscle relaxants and analgesics. Sci. Rep. 14, 1\u201322 (2024).","journal-title":"Sci. Rep."},{"key":"50549_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-55761-z","volume":"9","author":"A Czyrski","year":"2019","unstructured":"Czyrski, A. & Sznura, J. The application of Box-Behnken-Design in the optimization of HPLC separation of fluoroquinolones. Sci. Rep. 9, 1\u201310 (2019).","journal-title":"Sci. Rep."},{"key":"50549_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s43094-023-00509-w","author":"K Patel","year":"2023","unstructured":"Patel, K., Shah, U. A. & Patel, C. N. Box\u2013Behnken design-assisted optimization of RP-HPLC method for the estimation of evogliptin tartrate by analytical quality by design. Futur. J. Pharm. Sci. https:\/\/doi.org\/10.1186\/s43094-023-00509-w (2023).","journal-title":"Futur. J. Pharm. Sci."},{"key":"50549_CR72","unstructured":"ICH Official web site: ICH. https:\/\/www.ich.org\/page\/ich-guidelines"},{"key":"50549_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.greeac.2025.100209","volume":"12","author":"SF Hammad","year":"2025","unstructured":"Hammad, S. F., Hamid, M. A. A., Adly, L. & Elagamy, S. H. Comprehensive review of greenness, whiteness, and blueness assessments of analytical methods. Green Anal. Chem. 12, 100209 (2025).","journal-title":"Green Anal. Chem."},{"key":"50549_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.greeac.2025.100208","volume":"12","author":"RN Patel","year":"2025","unstructured":"Patel, R. N., Vegad, K. L., Mistry, R. V. & Patel, N. D. Greenness, blueness and whiteness evaluated rapid Attenuated Total Reflection\/ Fourier Transform Infrared Spectroscopy method for piper nigrum samples coupled with multivariate analysis. Green Anal. Chem. 12, 100208 (2025).","journal-title":"Green Anal. Chem."},{"key":"50549_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.talo.2024.100367","volume":"10","author":"EA Assirey","year":"2024","unstructured":"Assirey, E. A., katamesh, N. S. & Mohamed, M. A. Evaluating the greenness, blueness, and whiteness of spectroscopic and UPLC techniques for the simultaneous measurement of anti-glaucoma drugs and the preservation agent. Talanta Open 10, 100367 (2024).","journal-title":"Talanta Open"},{"key":"50549_CR76","doi-asserted-by":"publisher","first-page":"101013","DOI":"10.1016\/j.jpha.2024.101013","volume":"14","author":"L Yin","year":"2024","unstructured":"Yin, L. et al. Green analytical chemistry metrics for evaluating the greenness of analytical procedures. J. Pharm. Anal. 14, 101013 (2024).","journal-title":"J. Pharm. Anal."},{"key":"50549_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/separations9060147","author":"AH Almalki","year":"2022","unstructured":"Almalki, A. H. et al. Evaluation of greenness of LC-MS chromatographic methods for simultaneous analysis of mixtures of serotonin, dopamine, acetylcholine, GABA and glutamate: AGREE tool application. Separations https:\/\/doi.org\/10.3390\/separations9060147 (2022).","journal-title":"Separations"},{"key":"50549_CR78","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira, F., Wojnowski, W. & Tobiszewski, M. AGREE - Analytical GREEnness metric approach and software. Anal. Chem. 92, 10076\u201310082 (2020).","journal-title":"Anal. Chem."},{"key":"50549_CR79","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.4155\/bio-2023-0138","volume":"15","author":"MA Moffid","year":"2023","unstructured":"Moffid, M. A., Mostafa, E. A., Mahmoud, S. T. & Sayed, R. M. An eco-friendly Ultra-Performance Liquid Chromatography\u2013Mass Spectrometry method for quantification of Rivaroxaban and Ticagrelor in rat plasma: Grapefruit interactions. Bioanalysis 15, 1327\u20131341 (2023).","journal-title":"Bioanalysis"},{"key":"50549_CR80","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13065-024-01377-y","volume":"19","author":"MM Abd Elwahab","year":"2025","unstructured":"Abd Elwahab, M. M., Saad, S., Sheribah, Z. A. & El-Enany, N. Assessment of greenness, blueness, and whiteness profiles of a validated HPLC-DAD method for quantitation of Donepezil HCl and Curcumin in their laboratory prepared co-formulated nanoliposomes. BMC Chem. 19, 17 (2025).","journal-title":"BMC Chem."},{"issue":"1","key":"50549_CR81","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13065-025-01503-4","volume":"19","author":"S Pepakayala","year":"2025","unstructured":"Pepakayala, S., Ratnakaram, V. N., Zunjarrao, Y. & Lohia, Y. K. Correction Green and sustainable LC-APCI-MS\/MS method for simultaneous quantification of genotoxic nitrosamines in antidiabetic medication: sitagliptin. BMC Chem. 19(1), 135. https:\/\/doi.org\/10.1186\/s13065-025-01503-4 (2025).","journal-title":"BMC Chem."},{"key":"50549_CR82","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/analytica5030030","volume":"5","author":"FR Mansour","year":"2024","unstructured":"Mansour, F. R., P\u0142otka-Wasylka, J. & Locatelli, M. Modified GAPI (MoGAPI) tool and software for the assessment of method greenness: Case studies and applications. Analytica 5, 451\u2013457 (2024).","journal-title":"Analytica"},{"key":"50549_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfca.2026.108876","volume":"150","author":"Q Huang","year":"2026","unstructured":"Huang, Q. et al. An eco-friendly and rapid HPLC method for simultaneous determination of adenosine and ergothioneine in ten kinds of Cordyceps spp. samples with Blue applicability grade index assessment. J. Food Compos. Anal. 150, 108876 (2026).","journal-title":"J. Food Compos. Anal."},{"key":"50549_CR84","first-page":"67","volume":"13","author":"N Galv\u00e3o","year":"2025","unstructured":"Galv\u00e3o, N. & Kogawa, A. C. A green and lean method certified by NEMI, ESA, AGREE, GAPI and BAGI for the analysis of Ivermectin in injection solution for veterinary use. Braz. J. Anal. Chem. 13, 67\u201379 (2025).","journal-title":"Braz. J. Anal. Chem."},{"key":"50549_CR85","doi-asserted-by":"publisher","first-page":"7598","DOI":"10.1039\/D3GC02347H","volume":"25","author":"N Manousi","year":"2023","unstructured":"Manousi, N., Wojnowski, W., P\u0142otka-Wasylka, J. & Samanidou, V. Blue applicability grade index (BAGI) and software: A new tool for the evaluation of method practicality. Green Chem. 25, 7598\u20137604 (2023).","journal-title":"Green Chem."},{"key":"50549_CR86","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1556\/1326.2025.01387","volume":"37","author":"LA Al-Khateeb","year":"2025","unstructured":"Al-Khateeb, L. A. et al. Integrated RP-HPLC approach for concurrent assay and dissolution analysis of artemether and lumefantrine: Leveraging MoGSA and RAPI. Acta Chromatogr. 37, 605\u2013615 (2025).","journal-title":"Acta Chromatogr."},{"key":"50549_CR87","first-page":"1","volume":"16","author":"VM Goud","year":"2026","unstructured":"Goud, V. M. et al. Eco-conscious AQbD-guided stability-indicating RP-UPLC method for analysing Tovorafenib in bulk and dosage forms. Sci. Rep. 16, 1\u201317 (2026).","journal-title":"Sci. Rep."},{"key":"50549_CR88","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1039\/D4GC05298F","volume":"27","author":"PM Nowak","year":"2025","unstructured":"Nowak, P. M., Wojnowski, W., Manousi, N., Samanidou, V. & Plotka-Wasylka, J. Red analytical performance index (RAPI) and software: The missing tool for assessing methods in terms of analytical performance. Green Chem. 27, 5546\u20135553 (2025).","journal-title":"Green Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50549-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50549-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50549-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:02:37Z","timestamp":1778533357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50549-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50549"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50549-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14733"}}